StockData
HTFLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Heartflow, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$51.02+2.73 (+5.65%)

Close on Oct 19, 2026

Market cap
$4.41B
P/E (TTM)
–
Dividend yield
–

About Heartflow

Surgical & Medical Instruments & Apparatus, SIC 3841

Heartflow develops artificial intelligence and computational software to provide non-invasive diagnostic and management solutions for coronary artery disease. The company's core offering, the Heartflow Platform, utilizes deep learning and computational fluid dynamics to construct personalized 3D anatomical models of coronary arteries from coronary computed tomography angiography scans. Key offerings include Heartflow RoadMap Analysis, which visualizes anatomy to streamline radiology workflows; Heartflow FFR CT Analysis, which evaluates fractional flow reserve and blood flow restrictions; and Heartflow Plaque Analysis, which characterizes plaque composition and volume. Its customer base consists of hospitals, outpatient imaging centers, and clinicians such as radiologists and cardiologists.

The enterprise maintains an installed base exceeding 1,465 accounts across the United States. Its corporate headquarters are not identified in the provided disclosure. International clinical studies have evaluated the technology across sites in Europe, the United Kingdom, Japan, Korea, Australia, and Canada, while research also references a Dutch study site.

Summary of the business section of Heartflow's latest annual report, written by StockData.

Company profile

Company

Legal name
Heartflow, Inc.
Founded
2007
Headquarters
San Francisco, CA
Address
135 Main Street, Suite 1000 94105
Phone
(650) 241-1221
Employees
843, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
HTFL
Exchange
Nasdaq
IPO date
Aug 8, 2025
Shares outstanding
87M, Jul 31, 2026
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1464521
CUSIP
42238D107
ISIN
US42238D1072
EIN
26-0506743

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John C.M. FarquharChief Executive Officer, Director321,914
Campbell RogersChief Medical Officer244,328
Vikram VergheseChief Financial Officer155,183
Marie L. JonesChief Accounting Officer32,176
Jeffrey C. LightcapDirector6,991,237
Timothy C. BarabeDirector188,231
William C. WeldonDirector243,931
Casey M. TanseyDirector3,187,509
Wayne Joseph RileyDirector–
Julie A. CullivanDirector27,291
Partners Management LP HealthCorDirector0
Nicholas DowningDirector–

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 8, 2025IPOInitial public offering priced (424B4 prospectus)
Aug 7, 2025ListingRegistration of securities on an exchange (Form 8-A)
Jun 14, 2010Name changeName changed from Cardiovascular Simulation, Inc. to Heartflow, Inc.